NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES
申请人:University of Pittsburgh -- Of the Commonwealth System of Higher Education
公开号:US20140296294A1
公开(公告)日:2014-10-02
Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof:
wherein: R
1
and R
2
are independently H, alkyl, or alkenyl; R
3
is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R
4
and R
5
are independently a bond, alkylenyl, or alkenylenyl; each R
6
and R
7
is independently selected from the group consisting of OH, F, Cl, Br, I, (C
1
-C
6
)alkyl, alkoxy, amino, COOH, CONH
2
, SO
3
H, PO
3
H
2
, CN, SH, NO
2
and CF
3
; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
Cannabionid受体-2的反向拮抗剂包括由公式IV或其药学上可接受的盐所表示的化合物:其中:R1和R2独立地为H,烷基或烯基;R3是烷基,烯基,芳基,芳基烷基,芳基烯基,杂环基,杂环基烷基,杂环芳基,杂环芳基烷基;R4和R5独立地为键,烷基烯基或烯基烯基;每个R6和R7独立地从OH,F,Cl,Br,I,(C1-C6)烷基,烷氧基,氨基,COOH,CONH2,SO3H,PO3H2,CN,SH,NO2和CF3的组中选出;p和q独立地为0,1,2,3,4或5。此类化合物可用于治疗骨质疏松症或多发性骨髓瘤。